SynVent is Syngene’s platform for fully integrated therapeutic discovery and development across large and small molecules.
Emerging biopharma work at the forefront of science, often venturing into disease areas where little or no real-world data exists to work with or regulatory frameworks to work within.
Our Dedicated Centers offer dedicated multi-disciplinary scientific teams, support personnel, and a tailormade ring-fenced and fire-walled infrastructure as per client specifications to support their R&D goals
Centre for Advanced Protein Studies [CAPS] is a state-of-the-art advanced national facility located in the Syngene campus, Bangalore.
Antibody–drug conjugates (ADCs) are usually described as three-part medicines: an antibody finds the tumor, a linker holds the construct together, and a cytotoxic payload kills the cell. The antibody decides where an ADC can bind. The ADC linker payload combination largely decides what happens after binding—whether the ADC remains intact in blood, how efficiently the […]
